Cynata Therapeutics Ltd (ASX:CYP) CEO Dr Kilian Kelly speaks with Proactive following the completion of a strategic review of the company’s clinical development portfolio. The review incorporated a detailed assessment of all ongoing and planned clinical development programs with input from existing strategic partners, contract research organisations and clinical centres. Patient recruitment for the company’s Phase 2 aGvHD trial is expected to commence this quarter.
Cynata completes strategic review of development portfolio
